NCT07103655

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 132 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.

Conditions

• Hypertrophic Cardiomyopathy (HCM)

Interventions

Type	Name	Description
DRUG	mavacamten	Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.
DRUG	Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol	Administer an appropriate dose of beta-blockers according to the patient's tolerance.
DRUG	diltiazem	Administer an appropriate dose of diltiazem according to the patient's tolerance.

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-07-01
• Completion: 2027-01-01
• First posted: 2025-08-05
• Last updated: 2026-01-21

Locations

1 site across 1 country: China